IBJNews

Lilly competitor gets backing on diabetes drug

Back to TopCommentsE-mailPrintBookmark and Share

Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.

J&J is trying to beat to market similar drugs in development from Indianapolis-based Eli Lilly and Co., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co. and AstraZeneca Plc.

J&J submitted sufficient evidence that the drug canagliflozin is safe and effective, the panel of advisers to the Food and Drug Administration determined Thursday in a 10-5 vote. The panel also voted 8-7 that the New Brunswick, N.J.-based company’s pill raises concern about heart risks.

The once-a-day pill that expels sugar in the urine after it’s filtered from blood by the kidneys is part of a treatment group known as SGLT2 inhibitors that are intended to have fewer side effects, such as low blood sugar and weight gain, than current diabetes drugs.

“I have to say I found this drug very encouraging,” Rebecca Killion, a patient representative on the panel from Washington, D.C., said during the meeting. While the drug has some risks, it still “addresses concerns that patients have with struggling with weight loss that affects their disease and concerns all diabetics have with struggling with hypoglycemia.”

The FDA is scheduled to decide on canagliflozin by the end of March.

FDA staff said in a report earlier this week that while J&J’s studies showed the drug worked as well Merck & Co.’s second best-seller Januvia and a generic treatment called glimepiride, it may have heart risks. Studies for the drug J&J has proposed calling Invokana to treat adults with Type 2 diabetes showed a potentially higher risk for heart events in the first 30 days compared with a placebo, according to the Jan. 8 report.

J&J submitted interim results of a study called Canvas on the medicine’s cardiovascular effects.

The studies reviewed so far showed that during the first 30 days of the cardiovascular trial, 13 cardiovascular events occurred on canagliflozin and one on placebo, according to the FDA staff. The drug raises LDL, or bad cholesterol, which may lead to the heart risk, despite favorable changes in HDL, or good, cholesterol, blood pressure and body weight, staff said.

“It is unclear whether this is a spurious finding or a true increased risk of early CV events,” agency’s staff said.

Panel members said the only way to answer the question is to let J&J finish their trial.

J&J plans to complete its review of heart risks in 2015, the company said at the meeting.

Some panel members raised concern that the drug doesn’t work as well in diabetics who have moderate kidney impairment, a condition that can occur more often in those with the disease. At the same time, those patients also suffer increased side effects while on the medication.

“It is quite different in them than it is in the general population,” Julia Lewis, a professor of medicine in the Nephrology Department at Vanderbilt University School of Medicine in Nashville, Tenn. “I’m concerned about it doing more harm than good in them.”

Diabetes is the seventh-leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. The disease, defined by high levels of sugar in the blood, affected almost 26 million people in the U.S. in 2010, or about 8.3 percent of the population, the Atlanta-based CDC said.

“We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S.,” Peter Stein, the head of metabolism development and diabetes disease area leader at J&J’s Janssen unit, said in a statement.

There are 11 groups of diabetes drugs on the market, said Osama Hamdy, director of the obesity and inpatient diabetes programs at the Joslin Diabetes Center affiliated with Harvard Medical School in Boston. Most of the treatments stimulate the pancreas to secrete insulin or improve the body’s sensitivity to insulin, a hormone that helps control blood sugar.

SGLT2 inhibitors, like the one J&J developed, don’t cause low blood sugar or weight gain. As the first to work on the kidney, these drugs can be combined with any other diabetes medications for maximum effect, Hamdy said by phone.

Lilly and Boehringer Ingelheim, a closely held company based in Ingelheim, Germany, plan to apply for approval this year of their SGLT2 inhibitor empagliflozin, the companies said Jan. 7 in a statement.

New York-based Bristol-Myers and London-based AstraZeneca are working to address FDA concerns with their product dapagliflozin, and may resubmit an application for review in the middle of this year. The FDA sought more data on dapagliflozin after advisers determined the risks of bladder and breast cancer outweigh the benefits of the medicine.

J&J’s canagliflozin doesn’t show an increased risk of such malignancies, FDA staff said.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. what Steve is doing and if he is on another radio station. That is the station I will listen to.

  2. From the story: "The city of Indianapolis also will consider tax incentives and funding for infrastructure required for the project, according to IEDC." Why would the City need to consider additional tax incentives when Lowe's has already bought the land and reached an agreement with IEDC to bring the jobs? What that tells me is that the City has already pledged the incentives, unofficially, and they just haven't had time to push it through the MDC yet. Either way, subsidizing $10/hour jobs is going to do nothing toward furthering the Mayor's stated goal of attracting middle and upper-middle class residents to Marion County.

  3. Ron Spencer and the entire staff of Theater on the Square embraced IndyFringe when it came to Mass Ave in 2005. TOTS was not only a venue but Ron and his friends created, presented and appeared in shows which embraced the 'spirit of the fringe'. He's weathered all the storms and kept smiling ... bon voyage and thank you.

  4. Not sure how many sushi restaurants are enough, but there are three that I know of in various parts of downtown proper and all are pretty good.

  5. Rick, how does granting theright to marry to people choosing to marry same-sex partners harm the lives of those who choose not to? I cannot for the life of me see any harm to people who choose not to marry someone of the same sex. We understand your choice to take the parts of the bible literally in your life. That is fine but why force your religious beliefs on others? I'm hoping the judges do the right thing and declare the ban unconstitutional so all citizens of Wisconsin and Indiana have the same marriage rights and that those who chose someone of the same sex do not have less rights than others.

ADVERTISEMENT